Medical Developments International (ASX:MVP) has announced New Zealand’s St John Ambulance will stop using Entonox (Nitrous Oxide) for critical analgesia, instead exclusively using its drug Penthrox®.
The healthcare company says Penthrox® will be the only inhaled analgesic administered, for the leading provider of ambulance services in New Zealand.
Medical Developments says it expects similar things to happen with other ambulance services globally, especially in Europe as Penthrox® is rolled out.
The company says Penthrox® sales have recorded significant growth during FY17, and expect further growth in FY18.
Shares in Medical Developments International (ASX:MVP) are trading 0.83 per cent higher to $4.84.